Guggenheim analyst Debjit Chattopadhyay initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating and announces Price Target of $30.
Guggenheim Initiates Coverage On NewAmsterdam Pharma With Buy Rating, Announces Price Target of $30
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.